Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker BMY · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 20, 2026 | REBLOZYL LUSPATERCEPT-AAMT | BMY Celgene Corp | Biologic (BLA), supplement Labeling | BLA761136 ↗ |
| Oct 16, 2026 | DASATINIB, SPRYCEL DASATINIB | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021986 ↗ |
| Aug 31, 2026 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125377 ↗ |
| Aug 18, 2026 | BARACLUDE ENTECAVIR | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021798 ↗ |
| Aug 18, 2026 | BARACLUDE ENTECAVIR | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021797 ↗ |
| Aug 13, 2026 | ZENBEXUS IBERDOMIDE HYDROCHLORIDE | BMY Bristol Myers Squibb | New drug (NDA) Type 1 - New Molecular Entity | NDA221075 ↗ |
| Aug 12, 2026 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125554 ↗ |
| Jul 22, 2026 | REVLIMID LENALIDOMIDE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021880 ↗ |
| Jun 24, 2026 | ELIQUIS APIXABAN | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA202155 ↗ Letter or label ↗ |
| Jun 12, 2026 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125377 ↗ |
| Jun 8, 2026 | OPDUALAG NIVOLUMAB; RELATLIMAB-RMBW | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA761234 ↗ |
| May 12, 2026 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA), supplement Labeling | BLA761381 ↗ |
| May 12, 2026 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125554 ↗ |
| Apr 27, 2026 | REVLIMID LENALIDOMIDE | BMY Bristol Myers Squibb | New drug (NDA), supplement REMS | NDA021880 ↗ |
| Mar 20, 2026 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| Feb 27, 2026 | REBLOZYL LUSPATERCEPT-AAMT | BMY Celgene Corp | Biologic (BLA), supplement Labeling | BLA761136 ↗ |
| Nov 24, 2025 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA), supplement Efficacy | BLA761381 ↗ |
| Oct 27, 2025 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA), supplement Efficacy | BLA761381 ↗ |
| Oct 27, 2025 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA), supplement Efficacy | BLA761381 ↗ |
| Jul 1, 2025 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125554 ↗ Letter or label ↗ |
| May 23, 2025 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA), supplement Labeling | BLA761381 ↗ |
| May 23, 2025 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| May 23, 2025 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125377 ↗ Letter or label ↗ |
| Apr 17, 2025 | ELIQUIS APIXABAN | BMY Bristol Myers Squibb | New drug (NDA), supplement Efficacy | NDA202155 ↗ Letter or label ↗ |
| Apr 17, 2025 | ELIQUIS APIXABAN | BMY Bristol Myers Squibb | New drug (NDA), supplement Efficacy | NDA202155 ↗ Letter or label ↗ |
| Apr 11, 2025 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| Apr 11, 2025 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125377 ↗ Letter or label ↗ |
| Apr 8, 2025 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ Letter or label ↗ |
| Apr 8, 2025 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125377 ↗ Letter or label ↗ |
| Jan 28, 2025 | YERVOY IPILIMUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125377 ↗ Letter or label ↗ |
| Jan 16, 2025 | IDHIFA ENASIDENIB MESYLATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA209606 ↗ |
| Dec 27, 2024 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA) Type 9 - New indication submitted as di… | BLA761429 ↗ |
| Dec 27, 2024 | OPDIVO QVANTIG NIVOLUMAB; HYALURONIDASE-NVHY | BMY Bristol-Myers Squibb | Biologic (BLA) Type 3 - New Dosage Form | BLA761381 ↗ |
| Dec 18, 2024 | IDHIFA ENASIDENIB MESYLATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA209606 ↗ Letter or label ↗ |
| Dec 5, 2024 | REYATAZ ATAZANAVIR SULFATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA206352 ↗ |
| Dec 5, 2024 | REYATAZ ATAZANAVIR SULFATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021567 ↗ |
| Oct 3, 2024 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| Jul 31, 2024 | DASATINIB DASATINIB | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021986 ↗ |
| May 29, 2024 | ORENCIA ABATACEPT | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125118 ↗ |
| May 16, 2024 | REBLOZYL LUSPATERCEPT-AAMT | BMY Celgene Corp | Biologic (BLA), supplement Labeling | BLA761136 ↗ |
| Mar 6, 2024 | OPDUALAG NIVOLUMAB; RELATLIMAB-RMBW | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA761234 ↗ |
| Mar 6, 2024 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125554 ↗ |
| Mar 6, 2024 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| Jan 26, 2024 | OPDIVO NIVOLUMAB | BMY Bristol Myers Squibb | Biologic (BLA), supplement Efficacy | BLA125554 ↗ |
| Jan 19, 2024 | ORENCIA ABATACEPT | BMY Bristol Myers Squibb | Biologic (BLA), supplement Labeling | BLA125118 ↗ |
| Dec 21, 2023 | IDHIFA ENASIDENIB MESYLATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA209606 ↗ |
| Nov 8, 2023 | SUSTIVA EFAVIRENZ | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021360 ↗ Letter or label ↗ |
| Nov 8, 2023 | SUSTIVA EFAVIRENZ | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA020972 ↗ Letter or label ↗ |
| Nov 7, 2023 | REYATAZ ATAZANAVIR SULFATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA206352 ↗ Letter or label ↗ |
| Nov 7, 2023 | REYATAZ ATAZANAVIR SULFATE | BMY Bristol Myers Squibb | New drug (NDA), supplement Labeling | NDA021567 ↗ Letter or label ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates